StockNews.AI
ATNM
StockNews.AI
138 days

ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

1. A class action lawsuit has been filed against ATNM for misleading statements. 2. Investors from October 31, 2022, to August 2, 2024, may claim compensation. 3. The lawsuit suggests ATNM's FDA application is unlikely to be approved. 4. Misleading statements about ACTN's operations led to investor damages. 5. Potential plaintiffs must act by May 26, 2025, to join.

7m saved
Insight
Article

FAQ

Why Bearish?

Historical examples show legal actions can significantly depress stock prices, similar to outcomes seen with biotech firms facing regulatory hurdles.

How important is it?

Legal actions often deter investors and can impact stock valuations significantly, especially in the biotech sector.

Why Short Term?

The lawsuit could immediately affect investor sentiment and stock performance as news develops.

Related Companies

ALNYSRNEGERN
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. So What: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Actinium's data from Sierra Trial was unlikely to satisfy the U.S. Food and Drug Administration's ("FDA") guidelines for the acceptance and approval of Actinium's Iomab-B Biologics License Application ("BLA"); (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival ("OS") that Actinium provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Actinium's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4) as a result, defendants' positive statements about Actinium's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case_id=37511 https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:       Laurence Rosen, Esq.      Phillip Kim, Esq.      The Rosen Law Firm, P.A.      275 Madison Avenue, 40th Floor      New York, NY 10016      Tel: (212) 686-1060      Toll Free: (866) 767-3653      Fax: (212) 202-3827      [email protected]      www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News